KALA BIO, Inc.

US$0.16As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:KALAHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR (74.53%)
Div yield —
ROE (345.32%)
Biotechnology
Beta (5Y) (2.20)
PE TTM —
TSR TTM (99.60%)
Mkt cap US$3.015M
ROIC (85.30%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.182
17.00%
(60.85%)
Hold 9|7|4|9|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
—
—
—
—
9.99%
7.32%
5.51%
16.36%
Revenue$M
0.172
0.173
0.172
0.180
9.89%
10.71%
3.66%
4.01%
Peers (US$3.015M)
Cap (US$)
PE
2.990M
—
2.993M
0.870x
Capital
TTM
5Y
10Y
Leveragex
2.431
0.213
0.212
EBIT/Intx
0.762
0.805
0.853
Own earn%
110.98
(32.72)
(31.83)
Sh yield%
23.46
7.56
8.80
Owners
Insiders/Inst%
10.83
60.36
Short interest%
2.97
SBC / revenue%
3.87
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
10–23
$1 testx
−0.1
Incr. ROIC%
3